Alkermes Announces Shareholder Vote in Favor of Merger with Elan Drug Technologies

WALTHAM, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced that Alkermes shareholders have approved the merger of Alkermes and Elan Drug Technologies (“EDT”), the profitable drug formulation and manufacturing business unit of Elan Corporation, plc (NYSE: ELN) (“Elan”). Both businesses will be combined under Alkermes plc, a newly formed company domiciled in Ireland. Approximately 99.9% of the votes cast by Alkermes’ shareholders were in favor of adopting the business combination agreement and plan of merger. Alkermes currently anticipates that the business combination will close on Sept. 16, 2011. Following the merger, Alkermes plc will be listed on the NASDAQ stock exchange under Alkermes’ current ticker symbol “ALKS.”